Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 37 publications
Maximal use of 0.05% topical isotretinoin in patients with congenital ichthyosis results in low systemic exposure.
Journal: British journal of clinical pharmacology
Published: August 05, 2025
Topical Isotretinoin (TMB-001) Treatment for 12 Weeks Did Not Result in Clinically Relevant Laboratory Abnormalities in Participants with Congenital Ichthyosis in the Phase 2b CONTROL Study.
Journal: Dermatology and therapy
Published: January 31, 2023
Characteristics and outcomes for participants with congenital ichthyosis who responded to treatment with the topical isotretinoin formulation TMB-001: results from the Phase IIb CONTROL study.
Journal: Clinical and experimental dermatology
Published: December 20, 2022
Phase IIb randomized CONTROL study demonstrates a novel topical isotretinoin formulation, TMB-001, is safe and effective in participants with either recessive X-linked or autosomal recessive lamellar congenital ichthyosis.
Journal: Clinical and experimental dermatology
Published: October 18, 2022
The CONTROL study: A randomized, double-blind vehicle-controlled phase 2b study of novel topical isotretinoin formulation demonstrates improvement in recessive X-linked and autosomal recessive lamellar congenital ichthyosis.
Journal: Journal of the American Academy of Dermatology
Published: April 20, 2022
Real-world biologic and apremilast treatment patterns in patients with psoriasis and psoriatic arthritis.
Journal: Dermatology online journal
Published: October 19, 2021
Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5-year data from reSURFACE 1 and reSURFACE 2.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: September 24, 2021
Clinical implications and predictive values of early PASI responses to tildrakizumab in patients with moderate-to-severe plaque psoriasis.
Journal: The Journal of dermatological treatment
Published: March 08, 2021
Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2).
Journal: The British journal of dermatology
Published: February 04, 2021
Real-world biologic and apremilast treatment patterns and healthcare costs in moderate-to-severe plaque psoriasis.
Journal: Dermatology online journal
Published: February 02, 2021
Efficacy and safety of tildrakizumab 100 mg for plaque psoriasis in patients randomized to treatment continuation vs treatment withdrawal with retreatment upon relapse in reSURFACE 1.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: January 18, 2021
Efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 64-week phase 3 study (reSURFACE 1).
Journal: The Journal of dermatology
Published: October 14, 2020
Last Updated: 09/26/2026